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The frequency of genomic rearrangements in BRCA1 was assessed in 42 American families with breast and ovarian
cancer who were seeking genetic testing and who were subsequently found to be negative for BRCA1 and BRCA2
coding-region mutations. An affected individual from each family was tested by PCR for the exon 13 duplication
(Puget et al. 1999a) and by Southern blot analysis for novel genomic rearrangements. The exon 13 duplication
was detected in one family, and four families had other genomic rearrangements. A total of 5 (11.9%) of the 42
families with breast/ovarian cancer who did not have BRCA1 and BRCA2 coding-region mutations had mutations
in BRCA1 that were missed by conformation-sensitive gel electrophoresis or sequencing. Four of five families with
BRCA1 genomic rearrangements included at least one individual with both breast and ovarian cancer; therefore,
4 (30.8%) of 13 families with a case of multiple primary breast and ovarian cancer had a genomic rearrangement
in BRCA1. Families with genomic rearrangements had prior probabilities of having a BRCA1 mutation, ranging
from 33% to 97% (mean 70%) (Couch et al. 1997). In contrast, in families without rearrangements, prior prob-
abilities of having a BRCA1mutation ranged from 7% to 92% (mean 37%). Thus, the prior probability of detecting
a BRCA1 mutation may be a useful predictor when considering the use of Southern blot analysis for families with
breast/ovarian cancer who do not have detectable coding-region mutations.
Introduction
Numerous studies have estimated the frequency of
BRCA1 (MIM 113705) and/or BRCA2 (MIM 600185)
coding-region mutations in familial breast and ovarian
cancer (Narod et al. 1995; Couch et al. 1997; Ford et
al. 1998; Moslehi et al. 2000). The results of a hetero-
geneity analysis based on linkage data from the Breast
Cancer Linkage Consortium suggested that 88% of fam-
ilies with at least four cases of breast cancer diagnosed
at age !60 years and with at least one case of ovarian
cancer are attributable to BRCA1 or BRCA2. In families
with at least two cases of ovarian cancer and at least
four cases of breast cancer, the percentage of families
showing linkage to BRCA1 and BRCA2 increased to
100% (Ford et al. 1998). These data suggest that mu-
tations in BRCA1 and BRCA2 account for the over-
Received June 6, 2000; accepted for publication August 2, 2000;
electronically published September 7, 2000.
Address for correspondence and reprints: Dr. Barbara Weber, Uni-
versity of Pennsylvania Cancer Center, 316-A BRB 2/3, 421 Curie
Boulevard, Philadelphia, PA 19104. E-mail: weberb@mail.med.upenn
.edu
 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6704-0009$02.00
whelming majority of families with hereditary suscep-
tibility to both breast and ovarian cancer. However,
PCR-based mutation-detection assays, including direct
sequencing, identified BRCA1 mutations in only 63%
of families showing linkage to BRCA1. No differences
in sensitivity estimates were noted for sequencing, com-
pared with other methods (Ford et al. 1998). It has been
suggested that, in part, the discrepancy between linkage
data, which predict BRCA1 or BRCA2 mutations in
almost all carefully defined families with breast and
ovarian cancer, and the actual number of mutations de-
tected by PCR-based assays is because a significant pro-
portion of mutations may not be identifiable by these
methods.
The recent discovery of several genomic rearrange-
ments within BRCA1 and its regulatory regions pro-
vides evidence that mutations involving several kilo-
bases of genomic sequence in BRCA1 may account for
at least some of this discrepancy (Petrij-Bosch et al.
1997; Puget et al. 1997, 1999a, 1999b; Swensen et al.
1997; Montagna et al. 1999; Rohlfs et al. 2000). In
fact, the exon 13 duplication and the three BRCA1 ge-
nomic rearrangements described by Petrij-Bosch and
colleagues are significant founder mutations in United
Kingdom and Dutch populations, respectively (Petrij-
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Table 1
Families Screened for Genomic Rearrangements
Group and Frequency of Mutation
No. of
Families
American (42 families):
Breast cancers/family:
0 0
1–3 23
4 19
Ovarian cancers/family:
0 0
1 28
2 14
Breast and ovarian cancer in one individual/family:
0 29
1 13
Bosch et al. 1997; The BRCA1 Exon 13 Duplication
Screening Group 2000). However, no studies have eval-
uated the frequency of genomic rearrangements in
American families with breast/ovarian cancer who are
seeking genetic testing; therefore, the extent to which
these rearrangements are a source of false-negative test
results in this setting is unknown.
Almost all of the well-characterized genomic rear-
rangements in BRCA1 that have been described to date
are thought to result from Alu-mediated recombination
events that result in deletions, inversions, and dupli-
cations (Lehrman et al. 1985; Chen et al. 1989), con-
sistent with data suggesting that Alu sequences are
found at an increased frequency in BRCA1 intronic se-
quences relative to the rest of the genome (Smith et al.
1996). Of the published BRCA1 genomic rearrange-
ments, three deletions have been described in the 5′ re-
gion of BRCA1 encompassing exons 1 and 2 and up-
stream regulatory regions (Swensen et al. 1997; Puget
et al. 1999b). Three different deletions that involve exon
13 and surrounding regions have also been described
(Petrij-Bosch et al. 1997; Puget et al. 1999b). Two exon
17 deletions have been reported (Puget et al. 1997;
Montagna et al. 1999), and other deletions have been
found around exons 8, 15, and 22 of BRCA1 (Petrij-
Bosch et al. 1997; Puget et al. 1999b; Rohlfs et al.
2000).
Only one genomic rearrangement in BRCA2, in
which a 5-kb region of the gene was deleted around
exon 3, has been described (Nordling et al. 1998). Since
BRCA2 intronic sequence contains fewer Alu repeats
than does BRCA1, it is presumed that genomic rear-
rangements involving Alu-mediated recombination
events are less frequent. Peelen et al. (2000) recently
reported the results of screening 81 Dutch families with
breast and/or ovarian cancer for mutations in BRCA2,
using Southern blot analysis, and they found no aber-
rant restriction patterns, providing additional evidence
that BRCA2 genomic rearrangements are infrequent, at
least in the Dutch population.
To assess the frequency of BRCA1 genomic rear-
rangements in a subset of families seeking genetic test-
ing, 42 American families with breast and ovarian can-
cer were tested for rearrangements, by use of Southern
blot analysis, and were screened for the exon 13 du-
plication, by use of PCR (Puget et al. 1999a). The 42
families had previously been fully analyzed for BRCA1
and BRCA2 coding-region mutations, by use of con-
formation-sensitive gel electrophoresis followed by di-
rect sequencing of variant bands, and all were negative
prior to being screened for genomic rearrangements
(A.-M.Martin and K. L. Nathanson, unpublished data).
Families, Material, and Methods
Families
Families were ascertained from the Cancer Risk Eval-
uation Clinic at the University of Pennsylvania (1994–
98) or the Breast Cancer Evaluation Clinic at the Uni-
versity of Michigan (1992–94). They were eligible for
this study if they had at least one case of breast cancer
and one case of ovarian cancer in the same lineage. All
families sought evaluation for genetic susceptibility to
cancer and provided consent for genetic analysis, al-
though families ascertained before 1994 were aware that
genetic testing would take place at an undetermined time
in the future, since BRCA1 and BRCA2 had not yet
been isolated. Families with cases of male breast cancer
were included only if there were also a case of female
breast cancer and at least one case of ovarian cancer in
the same lineage. A DNA sample from at least one family
member who was affected with breast and/or ovarian
cancer and who was negative for coding-region and
splice-site mutations in both BRCA1 and BRCA2 was
used for Southern blotting and PCR-based genomic-re-
arrangement testing. When more than one sample was
available for testing, the woman with the youngest age
at diagnosis of breast cancer was selected. Three pro-
bands had breast/ovarian cancers in both the maternal
and paternal lineages. A total of 42 families were avail-
able for analysis (see table 1).
Exon 13 Duplication Screening
Genomic DNA was isolated from peripheral blood
lymphocytes or Epstein-Barr virus–immortalized lym-
phoblasts, by use of standard procedures. The primer
set (Dup13F 5′-GAT TAT TTC CCC CCA GGC TA-3′
and Dup13R 5′-AGA TCA TTA GCA AGG ACC TGT
G-3′), which was annealed at 58C in 1.5 mM (MgCl2),
generated a product of ∼1.1 kb in the presence of an
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Table 2
PCR Primers for Southern Blot Probes
Exon and
Primer Pair
Base
Pair Sequence
Product
Size
(bp)
Temperature
(C)
3:
SouEx3F 12386 5′-GTG GAT ATG GGT GAA ACA GC-3′ 1,863 58
SouEx3R 14228 5′-CCA GAA AAA TGT ACA TGG CC-3′ 58
8:
SouEx8F 28395 5′-GTT ATC AGA TGT GAT TGG AAT G-3′ 768 55
SouEx8R 29142 5′-TCT TTT GCT CCC TTT TTA AA-3′ 55
13:
SouEx13F 46120 5′-ATT TCA TTT TCT TGG TGC CA-3′ 1,645 58
SouEx13R 47744 5-′GGG AGA AAA AGG CTC AAA AC-3′ 58
14:
SouEx14F 51444 5′-CCT TCT TGT GCC ATT TCA TC-3′ 1,084 58
SouEx14R 52507 5′-ACC ATC AGT TTC CAA GCT TG-3′ 58
15:
SouEx15F 53422 5′-AAA AGG CAG GCA ATA GGG AT-3′ 1,211 60
SouEx15R 54632 5′-CCA AGA CTC CCT CAT CCT CA-3′ 60
16:
SouEx16F 57117 5′-AAT TAA TGG GTG AAG AGT ACT CC-3′ 1,338 56
SouEx16R 58434 5′-ACA GGG GTG GTA AAC TTC TC-3′ 56
17:
SouEx17F 60380 5′-TTT ATG TCT GCT GAT GTG TAC A-3′ 1,124 54
SouEx17R 61503 5′-AGA CTA TCA TCC ATG GTA TGC-3′ 54
20:
SouEx20F 71504 5′-CCT GAA TGC CTT TAA ATA TGA-3′ 715 53
SouEx20R 72218 5′-TAA ATT TTA GCT ATT ATT GGC TG-3′ 53
23–24:a
SouEx23F 80966 5′-TGA TGA AGT GAC AGT TCC AG-3′ 2,209 55
NOTE.—PCR amplification was performed with primers described elsewhere (Friedman et al. 1994),
for exons 1–2 (1,522 bp), 5–7 (2,508 bp), 9–10 (1,618 bp), 11–12 (1,657 bp), 18–19 (799 bp), and
21–22 (2,220 bp). In all cases, the forward primer from the first exon was paired with the reverse
primer from the second exon.
a Data for the 24R primer have been published elsewhere (Friedman et al. 1994).
exon 13 duplication. Because no product is obtained
from a normal allele, an internal PCR control amplifying
a region of BRCA1 exon 11 was performed on all ge-
nomic DNA before the exon 13 duplication screen. The
primers used for exon 11 of BRCA1 were as follows:
11F 5′-GGG AAA ACC TAT CGG AAG AA-3′ and 11R
5′-AGC CCA CTT CAT TAG TAC TGG AAC-3′. When
annealed at 55C, they generated a 1.7-kb PCR product.
Southern Blot Analysis
Southern blotting was performed using amodified ver-
sion of the protocol described by Puget et al. (1999b).
In brief, 10 mg genomic DNA were digested with ∼30
units of EcoRI, HindIII, or Xba1 for 5 h. Digestions
were run overnight on a 25-cm agarose gel (0.8%) at
60 V in 1 # Tris-borate EDTA buffer (Sambrook et al.
1989, pp. 7.01–7.87). Gels were denatured in 0.25 N
HCl for 15 min and in 0.5 N NaOH/1.5 N NaCl for
20 min with gentle shaking. Overnight, DNA was trans-
ferred to nylon membranes (Hybond N [Amersham])
in the alkali buffer.
To reduce exposure time, a series of longer probes
amplified from genomic DNA was designed over several
of the exons of BRCA1 (table 2). These probes were
pooled, in the same manner, into one of three hybridi-
zation mixtures, and they produced the same banding
pattern described by Puget et al. (1999b), with the ex-
ception of two additional fragments (2.9 kb each) that
were detected in introns 3 and 13 when the new probes
were used. With the longer probes, the exposure time
of the filters was reduced from ∼2 wk to 24–48 h.
DNA-containing membranes were prehybridized for
2 h in Church and Gilbert buffer (Church and Gilbert
1984) with denatured human placental DNA (Sigma),
5 mg/ml, at 65C. Approximately 50 ng of an equimolar
mixture of probes from exons 3–10 and 15–19, exons
11–14 and 20–24, or exons 1–2 were labeled with use
of the Random Primed DNA Labeling Kit (Roche) and
were prehybridized with human placental DNA, 0.1 mg/
ml, for 1 h at 65C. Each labeled probe mixture was
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Figure 1 Results of Southern blot analysis, for families 166 (F166), 440 (F440), and 531 (F531)
added to the prehybridization buffer and filter and was
hybridized overnight at 65C.
Filters were rinsed two times in 2# SSC, 0.1% SDS,
and then were washed one time in 1# SSC, 0.1% SDS,
for 15 min at room temperature. The stringency of the
washing conditions increased to one wash in 0.2# SSC,
0.1% SDS, at 65C for 20 min and one final wash at
0.1# SSC, 0.1% SDS, at 65C, if necessary. Filters were
exposed to a phosphoimager screen (Molecular Dynam-
ics) for 24–48 h and were analyzed using ImageQuant
Software. To hybridize each filter with three separate
probe mixtures, filters were stripped of probe by the
addition of boiling 0.1 # SSC, 0.1% SDS, for 20 min
at room temperature with shaking.
Results
Exon 13 Duplication
Prior to Southern blot analysis, genomic DNA from
an affected member from each family was analyzed for
the 6-kb duplication encompassing exon 13 of BRCA1
(Puget et al. 1999a). An exon 13 duplication was de-
tected in 1/42 families (data not shown). This family is
of English origin, which is consistent with the obser-
vation that the exon 13 duplication may be a founder
mutation from the Yorkshire region of the United
Kingdom (The BRCA1 Exon 13 Duplication Screening
Group 2000).
Southern Blot Analysis
Of the remaining 41 DNA samples that were tested
by Southern blot analysis, 4 showed evidence of genomic
rearrangements in BRCA1. In families 166 and 440,
Southern blot analysis showed extra bands in the EcoRI
and HindIII digests, respectively, when hybridized with
mix 3 probes (exons 1 and 2 of BRCA1). In family 166,
the additional band was accompanied by a reduction in
band intensity corresponding to the BRCA1 pseudogene
and the upstream regulatory region of BRCA1 on EcoRI
digestion (fig. 1a). In family 440, the extra band was
accompanied by a reduction in the band intensity cor-
responding to exons 1 and 2 of BRCA1 on HindIII di-
gestion (fig. 1b). The specific breakpoints of the rear-
rangements in families 166 and 440 are currently being
mapped.
An additional rearrangement encompassing exons
17–19 of BRCA1 was detected in family 531, by use of
Southern blotting. Hybridization of mix 1 (exons 3–10
and 15–19) detected, in an EcoRI digest, an additional
band below the normal band of 9.8 kb (exons 17–19)
but above the 5.7-kb band (exons 15–16) (fig. 1c). A
corresponding reduction in the intensity of the 9.8-kb
band in the EcoRI digest of this sample was seen. In
addition, the HindIII digest of this sample also provided
evidence of a rearrangement after hybridization with
mix 1. In the latter case, a reduction in the intensity of
the 19.0-kb band (exons 15–19) was detected (data not
shown), but no extra bands were detected. The specific
Unger et al.: BRCA1 Genomic Rearrangements 845
Figure 2 Summary of BRCA1 genomic rearrangements detected in the present study. A single asterisk (*) indicates screening and mapping
of this rearrangement was done as described elsewhere (Rohlfs et al. 2000). A double asterisk (**) denotes genomic rearrangements detected
in the present study.
breakpoints of this rearrangement are also currently be-
ing mapped.
The final family (family 30), of those in this sample
set, to have a genomic rearrangement detected has also
been described elsewhere (Rohlfs et al. 2000), since this
mutation was detected simultaneously using protein
truncation testing (PTT). This family has a 7.1-kb de-
letion of BRCA1 flanking exons 8–9. The location of
genomic rearrangements detected in this study is sum-
marized in figure 2.
In total, BRCA1 genomic rearrangements were de-
tected in 5/42 families. Three of the five families had six
or more cases of breast cancer and two or more cases
of ovarian cancer. Four of the five families included at
least one individual with both breast cancer and ovarian
cancer (table 3). Completion of the screen for BRCA1
genomic rearrangements led to the identification of 37
families who tested negative for coding-region, splice-
site, and genomic-rearrangement mutations in BRCA1
and for coding-region and splice-site mutations in
BRCA2. The “negative” cohort included six (16.2%)
families with six or more cases of breast cancer, 11
(29.7%) families with two or more cases of ovarian
cancer, and 9 (24.3%) families with at least one indi-
vidual with both breast cancer and ovarian cancer. Table
4 lists the probability of detecting a BRCA1 mutation
by use of the Couch model (Couch et al. 1997), for all
the families tested in the present study.
Discussion
Germline genomic rearrangements have been found to
be a cause of disease-associated germline mutations in
a variety of human genetic disorders, including several
cancer-susceptibility syndromes. In one recent study
(Stolle et al. 1998), genomic deletions in the VHL gene,
which is associated with von Hippel-Lindau disease,
were detected in 23 (25%) of 93 carriers of the VHL
mutation. Deletions of the entire gene were found in 8
(9%) of the 93 mutation carriers, for a combined fre-
quency of 34% for partial and complete genomic de-
letions (Stolle et al. 1998). Genomic rearrangements also
occur in the APC gene in association with familial ad-
enomatous polyposis, albeit at a frequency of !5% (van
der Luijt et al. 1997; Giarola et al. 1999). As commercial
testing for germline mutations in cancer-susceptibility
genes becomes a more routine part of medical practice
and as effective interventions are developed, genom-
ic rearrangements need to be carefully considered as a
cause of false-negative results following PCR-based
analysis, including sequencing. However, the frequen-
cy of genomic rearrangements in American families
with breast/ovarian cancer who are seeking genetic test-
ing for BRCA1 and BRCA2 mutations has not been
determined.
Two previous studies (Petrij-Bosch et al. 1997; Puget
et al. 1999b) have screened families forBRCA1 genomic
rearrangements, by means of Southern blot analysis.
The first study (Petrij-Bosch et al. 1997), in which a
clinically relevant series of Dutch families seeking ge-
netic testing was evaluated, provided evidence that
36% of BRCA1 mutations could be missed by failure
to screen for genomic rearrangements. In the second
study, Puget et al. (1999b) screened a mixed American/
French population and noted a strong founder effect
caused by the exon 13 duplication. The American fam-
ilies included in the series screened by Puget et al. were
selected from a group of families ascertained primarily
for linkage analysis. Thus, the data from this cohort
may not provide the information necessary to evaluate
the frequency of genomic rearrangements in a more clin-
ically relevant population of women seeking genetic
evaluation in the United States. It is also important to
know whether a few genomic rearrangements occur re-
peatedly (as in the Dutch population) or whether many
unique rearrangements can be detected (as would be
expected in our more heterogeneous population). Fi-
nally, it is important to identify individuals who might
best be targeted for further analysis after coding-region/
splice-site analysis fails to identify a mutation. There-
fore, to our knowledge, this is the first study to syste-
matically evaluate the frequency of BRCA1 genomic
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Table 3
Description of Families with Genomic Rearrangements
FAMILY (GENOMIC
REARRANGEMENT)
NO. OF CANCERS (MEDIAN AGE AT DIAGNOSIS [years])
ETHNICITYaBreast Ovarian
Multiple
Primary
Breast/
Ovarian Bilateral Other
30b (del exons 8–9) 10 (33) 3 2 3 0 Northern European
166 (exons 1–2) 3 (43) 1 1 1 0 Polish
440 (exons 1 and 2) 6 (50) 2 1 1 2c Western European
531 (exons 17–19) 5 (42) 1 0 0 4d Western European
771e (dup exon 13) 4 (41) 3 1 0 2f English
a Of lineage most likely to carry the mutation.
b Described by Rohlfs et al. (2000).
c Melanoma and pancreatic.
d Endometrial (2), leukemia, and melanoma.
e Described by the BRCA1 Exon 13 Duplication Screening Group (2000).
f Colon and cervical.
rearrangements in a cohort of American women from
families with breast/ovarian cancer who are seeking ge-
netic testing and who are negative for BRCA1 and
BRCA2 coding-regionmutations. Additional studies are
needed, but this study provides a starting point for con-
tinued investigation.
In the present study, we analyzed a series of families
with breast/ovarian cancer who were seeking genetic
testing and who had no detectable coding-region mu-
tations in BRCA1 or BRCA2, and we found genomic
rearrangements in 5 (11.9%) of 42 families. The novel
genomic rearrangement in family 166 is upstream of the
BRCA1 coding region and appears to involve the pro-
moter as well as the BRCA1 pseudogene. The dupli-
cated pseudogene region of BRCA1 is flanked by Alu
sequences (Brown et al. 1996); therefore, an Alu-me-
diated recombination event between the BRCA1 pseu-
dogene region and an Alu sequence in the 5′ region of
BRCA1 may have generated a deletion of critical bind-
ing sites in the BRCA1 promoter. The genomic rear-
rangements detected in families 440 and 531 are large
deletions of genomic sequence around exons 1–2 and
exons 17–19, respectively; these rearrangements pos-
sibly remove important functional domains and/or cre-
ate frameshift mutations. Additional mapping studies
of these three novel rearrangements are under way. The
rearrangement detected in family 771 is the previously
described exon 13 duplication, and the rearrangement
(a deletion of exons 8–9) in family 30 has been described
by Rohlfs et al. (2000).
This study was designed to address two questions.
The first question is whether there is evidence for ad-
ditional susceptibility genes in families who have mul-
tiple cases of breast and ovarian cancer but who do not
have detectable BRCA1 or BRCA2 coding regions, or
whether such cancers in these families are attributable
to genomic rearrangements in BRCA1 that are missed
by PCR-based mutation analysis. The second question
is which families are most likely to require additional
analyses in the setting of a negative BRCA1/2 coding-
region analysis, to maximize sensitivity.
In addressing the question of whether genomic re-
arrangements in BRCA1 can be detected in the majority
of families with breast/ovarian cancer who do not have
coding-region mutations, we detected rearrangements
in only 5/42 families. Thus, in our series, the results of
Southern blot analysis for genomic rearrangementswere
negative in 37/42 families. In the present study, all of
the families that are large enough to be informative are
consistent with autosomal dominant transmission of
breast cancer susceptibility; therefore, these data suggest
that other susceptibility genes or other as-yet-undetected
mutations in BRCA1 remain to be discovered in at least
some of these families. Because linkage analysis is not
possible in the majority of these families, as a result of
limited numbers of living affected individuals, we can-
not distinguish between these possibilities in this cohort.
All relevant studies to date suggest that a discrepancy
remains between the estimated 81% of families with
breast/ovarian cancer caused by BRCA1 mutations, as
predicted by linkage analysis (Ford et al. 1998), and the
mutation frequency estimates of 37%–71% in similar
families, even when including genomic rearrangements
(table 5). Differences in family ascertainment may ac-
count for some of the variability seen in BRCA1 mu-
tation frequency; however, there remains a proportion
of families with breast/ovarian cancer who show evi-
dence of linkage to BRCA1 in which mutations have
not been found.
Families without identifiable BRCA1 or BRCA2 mu-
tations after full analysis for coding-region mutations
and genomic rearrangements may still harbor BRCA1
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Table 4
Prior Probability of Detecting a BRCA1 Mutation in
Screened Families (Couch et al. 1997)
Family
No.
Predicted
Probability
(%) Ethnicitya
Genomic
Rearrangementb
30 96.6 W 
28 92.4 W 
771 88.5 W 
685 85.3 AJ 
236 78.5 AJ 
807 77.1 AJ 
440 75.4 W 
863 67.9 AJ 
1,112 67.9 AJ 
933 65.9 W 
166 57.1 W 
435 57.1 W 
96 55.0 W 
62 54.9 W 
299 54.9 W 
1,062 47.8 AJ 
497 45.7 AJ 
199 43.5 W 
592 43.5 W 
457 34.7 AJ 
85 32.7 W 
487 32.7 W 
531 32.7 W 
107 23.4 W 
142 23.4 W 
192 23.4 W 
230 23.4 W 
686 23.4 W 
792 23.4 W 
1,053 23.4 W 
165 16.2 W 
206 16.2 W 
232 16.2 W 
360 16.2 W 
372 16.2 W 
545 16.2 W 
651 16.2 W 
217 10.8 W 
340 7.1 W 
341 7.1 W 
445 7.1 W 
536 1.3 W 
a AJ p Ashkenazi Jewish; W p white.
b A plus sign () denotes a positive result; a minus
sign () denotes a negative result.
mutations. Mutations may be missed by Southern blot-
ting if the aberrant banding pattern is not discernible
by separation on an agarose gel. To date, the smallest
rearrangement in BRCA1 detected to date by Southern
blotting is 1 kb (Puget et al. 1997), and smaller rear-
rangements certainly may occur. In addition, it is pos-
sible that, although a portion of genomic rearrange-
ments are large enough to be detected by Southern blot
analysis, they cannot be identified by use of this tech-
nique because of the nature of the rearrangement. An
example is the BRCA1 exon 13 duplication. The first
family identified with this mutation was initially tested
by Southern blot analysis and was thought to be neg-
ative for genomic rearrangements. Subsequent use of
PCR-based screening of the mutant cDNA led to the
discovery and mapping of the duplication (Puget et al.
1999a). A recently described technique (Yan et al. 2000)
for converting cells to haploidy for genetic analysis may
be a useful tool for mutation detection in some families,
because it isolates the mutant allele from the wild type
so that the absence of a PCR product is not obscured
by a wild-type product.
The answer to the question of which families aremost
likely to require Southern blotting after a negative
BRCA1/2 coding-region analysis may be derived from
a description of the families with rearrangements. The
sample set used for this study consisted of families seek-
ing genetic analysis and is representative of the families
with breast/ovarian cancer who we continue to see in
our risk evaluation clinic, with respect to numbers of
affected individuals and the range of age at diagnosis,
suggesting that it is a valid source from which to begin
formulation of clinical recommendations. The five fam-
ilies with rearrangements had a range of 1–10 breast
cancers; three of the five families had two or more cases
of ovarian cancer, and four of the five families had at
least one individual with multiple primary breast/ovar-
ian cancer. Overall, in the present study, 4 (30%) of the
13 families who had a case of multiple primary breast/
ovarian cancer had a detectable genomic rearrange-
ment. Families with two or more cases of ovarian cancer
and/or at least one case of multiple primary breast/ovar-
ian cancer are relatively uncommon, even in a referral
clinic, and these features are strong predictors for the
presence of BRCA1 coding-region mutations. The fam-
ilies without rearrangements had a range of 1–8 cases
of breast cancer; 26/37 families had only one case of
ovarian cancer, and 9/37 families had an individual with
both breast cancer and ovarian cancer (table 3). These
data support the hypothesis that the higher the prior
probability of finding a BRCA1 mutation in a given
family, the more likely that Southern blot analysis will
provide clinically relevant information.
Indeed, in this study, the prior probabilities of having
a BRCA1mutation were between 33% and 97% (mean
70%) for the five families with genomic rearrangements
(table 4) (Couch et al. 1997). In the 37 families without
detectable genomic rearrangements, the mean prior
probability of having a BRCA1 mutation was 37%
(range 7%–92%). The mean prior probability in fam-
ilies with genomic rearrangements corresponds either to
a non-Ashkenazi Jewish family with at least one case
of multiple primary breast/ovarian cancer and an av-
erage age at diagnosis of 35–39 years or to an Ashkenazi
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Table 5
Comparison of BRCA1 and BRCA2 Mutation Frequencies in Families with Breast and Ovarian Cancer
NO. OF OVARIAN CASES FOR
ASCERTAINMENT AND SOURCE
NO. (%) OF FAMILIES
GEOGRAPHIC
SOURCE
Positive for
Negative
for
BRCA1/2
With BRCA1
Genomic
RearrangementsBRCA1 BRCA2 Total
11:
Ford et al. (1998) 76 (80.9%) 13 (13.8%) 5 (5.3%) Not tested 94 North America and western
Europe
Moslehi et al. (2000) 25 (50.0%) 8 (16%) 17 (34.0%) Not tested 50 North America and Israel
Levy-Lahad et al. (1997)a 7 (36.8%) 5 (26.4%) 7 (36.8%) Not tested 19 Israel
O. Sinilnikova and S. Mazoyer
(unpublished data)
29 (60.4%) 3 (6.3%) 11 (22.9%) 5 (10.4%) 48 United Kingdom
Martin et al. (unpublished data) 55 (51.9%) 7 (6.6%) 39 (36.8%)b 5 (4.7%) 106 United States
2:
Gayther et al. (1999) 32 (51.6%) 6 (9.6%) 24 (38.8%) Not tested 62 United States
a This study only measured the frequency of Ashkenazi Jewish founder mutations.
b The families that tested negative for BRCA1 and BRCA2 mutations in the study by Martin et al. (unpublished data) were the families that
were tested for BRCA1 genomic rearrangements in the present study (see the Families, Material, and Methods section).
Jewish family with at least one breast cancer, one ovar-
ian cancer, and a mean age at diagnosis of !50 years.
In the families without rearrangements, the mean prior
probability (37%) of having a BRCA1 mutation cor-
responds either to a non-Ashkenazi Jewish family with
at least one case of breast cancer, one case of ovarian
cancer, and a mean age at diagnosis of !50 years or to
an Ashkenazi Jewish family with at least one case of
breast cancer, one case of ovarian cancer, and a mean
age at diagnosis of 160 years. Whereas the present study
is limited by a small sample size and was not designed
to provide a comprehensive survey of the frequency and
type of BRCA1 rearrangements, the data do suggest
that, in families with a high likelihood of havingBRCA1
mutations, genomic rearrangements represent a source
of false-negative test results. Again, bearing in mind the
small sample set, false-negative results from PCR-based
methodologies may be as high as 30% in American
families with at least one case of multiple primary
breast/ovarian cancer. Taken together, these data suggest
that testing for genomic rearrangements might be con-
sidered in families with a prior probability of 30% of
having a BRCA1 mutation.
On the basis of the data in the present study, com-
parison of the relative frequency of BRCA1 andBRCA2
coding-region mutations and genomic rearrangements
in similar populations suggests that the frequency of
BRCA1 genomic rearrangements in families with
breast/ovarian cancer is equal to or greater than the
frequency of BRCA2 coding-region mutations (table 5).
In support of this observation, data from a study (O.
Sinilnikova and S. Mazoyer, unpublished data) of 48
breast and ovarian cancer families with one or more
cases of ovarian cancer show BRCA1 genomic rear-
rangements in 10% of families, whereas BRCA2 coding
and splice-site mutations were detected in 6%. A third
study provides additional data on the frequency of
BRCA2 coding-region and splice-site mutations in fam-
ilies in the United Kingdomwho have two or more cases
of ovarian cancer and a history of breast cancer; mu-
tations were found in 10% of these families (Gayther
et al. 1999). Although a genomic-rearrangement screen
has not yet been performed on the cohort from the
United Kingdom, the BRCA2 mutation frequency is
consistent with results of previous studies of non-Ash-
kenazi Jewish families. Thus, data from several sources
suggest that analysis for BRCA1 genomic rearrange-
ments in families with breast/ovarian cancer may yield
as many mutations as does BRCA2 coding-region
screening in non-Ashkenazi Jewish families with breast/
ovarian cancer, a current standard of practice.
In summary, this study provides evidence that ge-
nomic rearrangements are a source of false-negative
test results in a clinically relevant population of Amer-
ican families with breast/ovarian cancer. When the mu-
tation frequency from coding-region analysis as well as
genomic-rearrangement screening in BRCA1 are com-
bined, they approach but do not fully account for link-
age-based estimates of the proportion of families with
breast/ovarian cancer caused by germline mutations in
BRCA1. To maximize sensitivity, genomic-rearrange-
ment analyses, including Southern blotting, PTT, and
other analyses, may need to be incorporated into mu-
tation testing for families with breast/ovarian cancer
who have high predicted probabilities of having a
BRCA1 mutations. A reasonable guide may be to con-
sider Southern blot analysis for those families who have
a predicted probability of 30% of having a BRCA1
mutation and who are found to be negative for BRCA1
and BRCA2 mutations by use of PCR-based methods
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but to recognize that additional studies must be per-
formed to validate this suggestion.
Acknowledgments
We would like to acknowledge William A. Ihlenfeld, Victor
Lai, and Theresa Colligan for technical support. We would
also like to thank the families for their participation. This work
was supported by NIH grant RO-1 CA76417-03 and a Breast
Cancer Research Foundation grant (to B.L.W.).
Electronic-Database Information
Accession numbers and the URL for data in this article are
as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for BRCA1 [MIM 113705], for
BRCA2 [MIM 600185])
References
BRCA1 Exon 13 Duplication Screening Group, The (2000)
The exon 13 duplication in the BRCA1 gene is a founder
mutation present in geographically diverse populations. Am
J Hum Genet 67:207–212
BrownMA, Xu CF, Nicolai H, Griffiths B, Chambers JA, Black
D, Solomon E (1996) The 5′ end of the BRCA1 gene lies
within a duplicated region of human chromosome 17q21.
Oncogene 12:2507–2513
Chen SJ, Chen Z, Font MP, d’Auriol L, Larsen CJ, Berger R
(1989) Structural alterations of the BCR and ABL genes in
Ph1 positive acute leukemias with rearrangements in the
BCR gene first intron: further evidence implicating Alu se-
quences in the chromosome translocation. Nucleic Acids Res
17:7631–7642
Church GM, Gilbert W (1984) Genomic sequencing. Proc Nat
Acad Sci USA 81:1991–1995
Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer
J, Campeau L, Ganguly A, Rebbeck T, Weber BL (1997)
BRCA1 mutations in women attending clinics that evaluate
the risk of breast cancer. N Engl J Med 336:1409–1415
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee
P, Bishop DT, et al (1998) Genetic heterogeneity and pen-
etrance analysis of the BRCA1 and BRCA2 genes in breast
cancer families. Am J Hum Genet 62:676–689
Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED,
Rowell SE, King M-C (1994) Confirmation of BRCA1 by
analysis of germline mutations linked to breast and ovarian
cancer in ten families. Nat Genet 8:399–404
Gayther SA, Russell P, Harrington P, Antoniou AC, Easton
DF, Ponder BAJ (1999) The contribution of germline
BRCA1 and BRCA2 mutations to familial ovarian cancer:
no evidence for other ovarian cancer-susceptibility genes.
Am J Hum Genet 65:1021–1029
Giarola M, Stagi L, Presciuttini S, Mondini P, Radice MT, Sala
P, Pierotti MA, Bertario L, Radice P (1999) Screening for
mutations of the APC gene in 66 Italian familial adenoma-
tous polyposis patients: evidence for phenotypic differences
in cases with and without identified mutation. Hum Mutat
13:116–123
Lehrman MA, Schneider WJ, Sudhof TC, Brown MS, Gold-
stein JL, Russell DW (1985) Mutation in LDL receptor:Alu-
Alu recombination deletes exons encoding transmembrane
and cytoplasmic domains. Science 227:140–146
Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich
G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A,
Halle D (1997) Founder BRCA1 and BRCA2 mutations in
Ashkenazi Jews in Israel: frequency and differential pene-
trance in ovarian cancer and in breast-ovarian cancer fam-
ilies. Am J Hum Genet 60:1059–1067
Montagna M, Santacatterina M, Torri A, Menin C, Zullato
D, Chieco-Bianchi L, D’Andrea E (1999) Identification of a
3 kb Alu-mediated BRCA1 gene rearrangement in two
breast/ovarian cancer families. Oncogene 18:4160–4165
Morgan NV, Tipping AJ, Joenje H, Mathew CG (1999) High
frequency of large intragenic deletions in the Fanconi anemia
group A gene. Am J Hum Genet 65:1330–1341
Moslehi R, Chu W, Karlan B, Fishman D, Risch A, Smotkin
D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung
N, Warner E, Rosen B, Friedman J, Brunet J-S, Narod SA
(2000) BRCA1 and BRCA2 mutation analysis of 208 Ash-
kenazi Jewish women with ovarian cancer. Am J HumGenet
66:1259–1272
Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT,
Smith SA, Ponder BA, et al (1995) An evaluation of genetic
heterogeneity in 145 breast-ovarian cancer families. Am J
Hum Genet 56:254–264
Nordling M, Karlsson P, Wahlstrom J, Engwall Y, Wallgren
A, Martinsson T (1998) A large deletion disrupts the exon
3 transcription activation domain of the BRCA2 gene in a
breast/ovarian cancer family. Cancer Res 58:1372–1375
Peelen T, van Vliet M, Bosch A, Bignell G, Vasen HF, Klijn
JG, Meijers-Heijboer H, Stratton M, van Ommen GJ, Cor-
nelisse CJ, Devilee P (2000) Screening for BRCA2mutations
in 81 Dutch breast-ovarian cancer families. Br J Cancer 82:
151–156
Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer
R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ,
Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF,
Cornelisse CJ, van’t Veer LJ, Bakker E, van Ommen GJ,
Devilee P (1997) BRCA1 genomic deletions are major
founder mutations in Dutch breast cancer patients. Nat
Genet 17:341–345
Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C,
Pages S, Lynch HT, Goldgar D, Lenior GM, Mazoyer S
(1999a) An Alu-mediated duplication in the BRCA1 gene:
a new founder mutation? Am J Hum Genet 64:300–302
Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch
HT, Lenoir GT, Mazoyer S (1999b) Screening for genomic
rearrangements and regulatory mutations in BRCA1 led to
the identification of four new deletions. Cancer Res 59:
455–461
Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT,
Feunteun J, Lenoir GM, Mazoyer S (1997) A 1-kb Alu-
mediated germ-line deletion removing BRCA1 exon 17.
Cancer Res 57:828–831
Rohlfs EM, Puget N, Graham ML, Weber BL, Garber JE,
Skrzynia C, Halperin JL, Lenior GM, Silverman LM, Ma-
850 Am. J. Hum. Genet. 67:841–850, 2000
zoyer S (2000) An Alu-mediated 7.1 kb deletion of BRCA1
exons in 8 and 9 in breast and ovarian cancer families that
results in alternate splicing of exon 10. Genes Chromosome
Cancer 28:300–307
Sambrook J, Fritsch E, Maniatis T (1989) Molecular cloning:
a laboratory manual, 2d ed. Vol 1. Cold Spring Harbor Lab-
oratory Press, Plainview, NY
Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor
M, Hood L, King MC (1996) Complete genomic sequence
and analysis of 117 kb of human DNA containing the gene
BRCA1. Genome Res 6:1029–1049
Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther
M, Pack S, Hurley K, Andrey C, Klausner R, Linehan WM
(1998) Improved detection of germline mutations in the von
Hippel-Lindau disease tumor suppressor gene. Hum Mutat
12:417–423
Swensen J, Hoffman M, Skolnick MH, Neuhausen SL (1997)
Identification of a 14 kb deletion involving the promoter
region of BRCA1 in a breast cancer family. HumMol Genet
6:1513–1517
van der Luijt RB, Khan PM, Vasen HF, Tops CM, van Leeu-
wen-Cornelisse IS, Wijnen JT, van der Klift HM, et al (1997)
Molecular analysis of the APC gene in 105 Dutch kindreds
with familial adenomatous polyposis: 67 germlinemutations
identified by DGGE, PTT, and southern analysis. Hum Mu-
tat 9:7–16
Yan H, Papadopoulos N,Marra G, Perrera C, Jiricny J, Boland
CR, Lynch HT, et al (2000) Conversion of diploidy to hap-
loidy. Nature 403:723–724
